Overview

Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this trial was to investigate safety, tolerability, and pharmacokinetics of BI 201335 ZW after administration of single rising doses from 40 mg to 480 mg of BI 201335 NA in healthy Japanese male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim